Figure 2.

Ten-year cost-effectiveness acceptability curves for lung volume reduction surgery (LVRS) versus medical therapy for all patients and for three subgroups with significantly improved clinical outcomes in the LVRS arm (reduced mortality, improved quality of life, or both). The curve represents the probability that LVRS is associated with a cost per quality-adjusted life-year (QALY) gained that is lower than the corresponding cost-effectiveness ratios displayed on the x axis. The value of the ceiling ratio at a probability of 0.5 is the median cost per QALY for LVRS. Solid horizontal lines denote 95% confidence limits for the projections.